Allosteric Modulation of Protein Arginine Methyltransferase 5 (PRMT5)

被引:27
|
作者
Palte, Rachel L. [1 ]
Schneider, Sebastian E. [1 ]
Altman, Michael D. [1 ]
Hayes, Robert P. [2 ]
Kawamura, Shuhei [1 ]
Lacey, Brian M. [1 ]
Mansueto, My Sam [1 ]
Reutershan, Michael [1 ]
Siliphaivanh, Phieng [1 ]
Sondey, Christopher [1 ]
Xu, Haiyan [1 ]
Xu, Zangwei [1 ]
Ye, Yingchun [1 ]
Machacek, Michelle R. [1 ]
机构
[1] Merck & Co Inc, Computat & Struct Chem, Boston, MA 02115 USA
[2] Computat & Struct Chem, West Point, PA 19486 USA
来源
ACS MEDICINAL CHEMISTRY LETTERS | 2020年 / 11卷 / 09期
关键词
PRMT5; allosteric inhibition; methyltransferase; peptide competitive; SAM competitive; crystal structure; SELECTIVE INHIBITOR; METHYLATION; POTENT; DISCOVERY; DELETION; HISTONE;
D O I
10.1021/acsmedchemlett.9b00525
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein arginine methyltransferase 5 (PRMT5) belongs to a family of enzymes that regulate the posttranslational modification of histones and other proteins via methylation of arginine. Methylation of histones is linked to an increase in transcription and regulates a manifold of functions such as signal transduction and transcriptional regulation. PRMT5 has been shown to be upregulated in the tumor environment of several cancer types, and the inhibition of PRMT5 activity was identified as a potential way to reduce tumor growth. Previously, four different modes of PRMT5 inhibition were known-competing (covalently or non-covalently) with the essential cofactor Sadenosyl methionine (SAM), blocking the substrate binding pocket, or blocking both simultaneously. Herein we describe an unprecedented conformation of PRMT5 in which the formation of an allosteric binding pocket abrogates the enzyme's canonical binding site and present the discovery of potent small molecule allosteric PRMT5 inhibitors.
引用
收藏
页码:1688 / 1693
页数:6
相关论文
共 50 条
  • [31] EFFECT OF THE PROTEIN ARGININE METHYLTRANSFERASE PRMT5 INHIBITION IN GLIOMA STEM-LIKE CELLS
    Mittal, Sandeep
    Shaw, Vikram
    Piao, Yuji
    Park, Soon Young
    Sriram, Sai
    Dong, Jianwen
    Martinez-Ledesma, Emmanuel
    Henry, Verlene
    Ezhilarasan, Ravesanker
    Sulman, Erik
    Balasubramaniyan, Veerakumar
    de Groot, John
    NEURO-ONCOLOGY, 2018, 20 : 87 - 87
  • [32] Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer
    Sapir, Tzuriel
    Shifteh, David
    Pahmer, Moshe
    Goel, Sanjay
    Maitra, Radhashree
    MOLECULAR CANCER RESEARCH, 2021, 19 (03) : 388 - 394
  • [33] Alternative Splicing Analysis Reveals Adrenergic Signaling as a Novel Target for Protein Arginine Methyltransferase 5 (PRMT5) in the Heart
    Jiao, Shouye
    Zhang, Yimeng
    Yang, Xiao
    Wang, Jian
    Li, Zhenhua
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [34] Structural insights into protein arginine symmetric dimethylation by PRMT5
    Sun, Litao
    Wang, Mingzhu
    Lv, Zongyang
    Yang, Na
    Liu, Yingfang
    Bao, Shilai
    Gong, Weimin
    Xu, Rui-Ming
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (51) : 20538 - 20543
  • [35] The protein arginine methyltransferase PRMT5 promotes D2-like dopamine receptor signaling
    Likhite, Neah
    Jackson, Christopher A.
    Liang, Mao-Shih
    Krzyzanowski, Michelle C.
    Lei, Pedro
    Wood, Jordan F.
    Birkaya, Barbara
    Michaels, Kerry L.
    Andreadis, Stelios T.
    Clark, Stewart D.
    Yu, Michael C.
    Ferkey, Denise M.
    SCIENCE SIGNALING, 2015, 8 (402)
  • [36] Identification of protein arginine N-methyltransferase 5 (PRMT5) as a novel interacting protein with the tumor suppressor protein RASSF1A
    Sakai, Nobuya
    Saito, Yumiko
    Fujiwara, Yoko
    Shiraki, Takashi
    Imanishi, Yorihisa
    Koshimizu, Taka-aki
    Shibata, Katsushi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 467 (04) : 778 - 784
  • [37] Discovery of new potent protein arginine methyltransferase 5 (PRMT5) inhibitors by assembly of key pharmacophores from known inhibitors
    Zhu, Kongkai
    Song, Jia-Li
    Tao, Hong-Rui
    Cheng, Zhi-Qiang
    Jiang, Cheng-Shi
    Zhang, Hua
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (23-24) : 3693 - 3699
  • [38] Developing a first in class of drug to inhibit protein arginine methyltransferase 5 (PRMT5) enzyme dysregulation in glioblastoma multiforme.
    Yan, Fengting
    Gordon, Kate
    Mahasenan, Kiran
    Lustberg, Mark
    Alinari, Lapo
    Earl, Christian T.
    Kaur, Balveen
    Li, Chenglong
    Baiocchi, Robert A.
    CANCER RESEARCH, 2013, 73 (08)
  • [39] Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma
    Yan, Fengting
    Smith, Porsha
    Alinari, Lapo
    Ryu, John
    Yu, Bo
    Karkhanis, Vrajesh
    Tae, Sookil
    Patton, John T.
    Wilding, Emily E.
    Gordon, Kate
    Mahasenan, Kiran
    Bhasin, Deepak
    Agostinelli, Claudio
    Pileri, Stefano A.
    Byrd, John C.
    Sif, Said
    Li, Pui-kai
    Li, Chenglong
    Baiocchi, Robert A.
    BLOOD, 2011, 118 (21) : 274 - 274
  • [40] Identification and validation of anti-protein arginine methyltransferase 5 (PRMT5) antibody as a novel biomarker for systemic sclerosis (SSc)
    Liang, Minrui
    Wang, Lingbiao
    Tian, Xiaolong
    Wang, Kun
    Zhu, Xiaoyi
    Huang, Linlin
    Li, Qing
    Ye, Wenjing
    Chen, Chen
    Yang, Haihua
    Wu, Wanqing
    Chen, Xiangjun
    Zhu, Xiaoxia
    Xue, Yu
    Wan, Weiguo
    Wu, Yanling
    Lu, Liwei
    Wang, Jiucun
    Zou, Hejian
    Ying, Tianlei
    Zhou, Feng
    ANNALS OF THE RHEUMATIC DISEASES, 2024, 83 (09) : 1144 - 1155